コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ent randomization (784 to placebo and 781 to levofloxacin).
2 acin-containing therapy (PPI + amoxicillin + levofloxacin).
3 did not differ significantly from that with levofloxacin.
4 le with poor dentition that was treated with levofloxacin.
5 pp mutant of CO92 and given the same dose of levofloxacin.
6 family Enterobacteriaceae were resistant to levofloxacin.
7 ng women initiated therapy with ofloxacin or levofloxacin.
8 patients who were treated for pneumonia with levofloxacin.
9 e to vancomycin and >90% were susceptible to levofloxacin.
10 e susceptible to penicillin, cefotaxime, and levofloxacin.
11 aluable precursor of the antimicrobial agent Levofloxacin.
12 scular mortality related to azithromycin and levofloxacin.
13 s a key precursor of the antimicrobial agent Levofloxacin.
14 ed to investigate the efficacy and safety of levofloxacin.
15 oxifloxacin, and 1.41 (95% CI, .91-2.18) for levofloxacin.
16 The infection was successfully treated with levofloxacin.
17 0.25 mug/ml), ethambutol (0.25 to 2 mug/ml), levofloxacin (0.12 to 1 mug/ml), moxifloxacin (0.06 to 0
18 ent for the individuals drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin,
19 ities were the following: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95.0%; tobramycin, 90
20 (10/31) and 54.5% of patients randomized to levofloxacin (18/33, P = .094) completed prophylaxis.
22 r ciprofloxacin, 2.41 (95% CI, .76-7.68) for levofloxacin, 2.00 (95% CI, 1.06-3.79) for norfloxacin,
23 se rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram per day) for the first
25 fluoroquinolones included 22 of 52 (42%) to levofloxacin, 20 of 54 (37%) to ciprofloxacin, 16 of 47
26 8) for metronidazole, 18% (95% CI 15-22) for levofloxacin, 3% (95% CI 2-5) for amoxicillin, and 4% (9
27 or a 10-day modified sequential therapy with Levofloxacin 500 mg id instead of Clarithromycin (group
28 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg t
29 followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg t
30 1 g/d) for 3 days followed by 7 days of oral levofloxacin (500 mg once daily) and metronidazole (500
31 ducted to compare the efficacy and safety of levofloxacin (500 mg q24h for 9 months) initiated in pat
32 omly assigned to receive a 3-month course of levofloxacin (500 mg/d; n = 76) or placebo (n = 78) star
33 gle-dose azithromycin (500 mg; 106 persons), levofloxacin (500 mg; 111 persons), or rifaximin (1650 m
34 to erythromycin (94.1%) and, less commonly, levofloxacin (54.6%), in addition to beta-lactam agents.
35 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5%; oxacillin, 54.7%; ciprofloxacin, 51
38 n, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; an
39 xacin, 129 microM; gatifloxacin, 130 microM; levofloxacin, 915 microM; and ciprofloxacin, 966 microM.
40 indamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addition to beta-lactam agents.
42 r uveitis, while current first-time users of levofloxacin (adjusted rate ratio, 1.26 [95% CI, 0.90-1.
43 tribution of the pretreated barley straw for levofloxacin adsorption was estimated based on the equil
46 r amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pneumoniae and for trimethoprim/su
47 m (S), 19 to 27 mm (I), and </=18 mm (R) for levofloxacin and >/=25 mm (S), 16 to 24 mm (I), and </=1
48 coccal isolates resistant or intermediate to levofloxacin and 124 pneumococcal isolates susceptible t
50 The critical concentration established for levofloxacin and amikacin was 1.5 microg/ml, that establ
53 When concentrations of various antibiotics (levofloxacin and linezolid) are pumped through the chann
55 published MIC breakpoints for Salmonella to levofloxacin and ofloxacin, but breakpoints for assignin
56 breakpoints in the MIC zone scattergrams for levofloxacin and ofloxacin, the following disk diffusion
58 to vancomycin (100%), linezolid (>99%), and levofloxacin and tigecycline (both >96%); imipenem susce
59 om 1.0-16.6% for ofloxacin, to 0.5-12.4% for levofloxacin, and 0.9-14.6% for moxifloxacin when tested
60 008 microg/ml) was slightly more active than levofloxacin, and E-test results were generally elevated
61 intermediate to high MICs for moxifloxacin, levofloxacin, and gentamicin were also observed among th
63 y broth microdilution against ciprofloxacin, levofloxacin, and ofloxacin and by disk diffusion using
65 diameters for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxacin were determined for 100 clin
66 2-agent combinations of amikacin, doripenem, levofloxacin, and rifampin were quantitatively assessed
67 ommon (3.8%, 4.4%, and 1.9% in azithromycin, levofloxacin, and rifaximin arms, respectively) (P = .55
69 ee new generation quinolones: trovafloxacin, levofloxacin, and sparfloxacin) on the DNA cleavage/reli
70 ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, and trovafloxacin were above the maximal s
71 erial infections, treatment with vancomycin, levofloxacin, and voriconazole prophylaxis resulted in n
75 Treatments were saline (negative control), levofloxacin at 15 mg/kg every 12 h (positive control),
77 s occurred in 81.4%, 78.3%, and 74.8% of the levofloxacin, azithromycin, and rifaximin arms, respecti
78 o compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadruple therapies as fir
80 treatment was significantly higher than with Levofloxacin-based therapy (90%, CI95%: 84-96% vs. 79%,
81 s within the triple therapy; moxifloxacin or levofloxacin-based triple therapy were both associated w
82 cultures were resistant to ciprofloxacin and levofloxacin, but all 15 strains were susceptible to spa
83 Very major discrepancies were not seen with levofloxacin, but occurred with clarithromycin in five s
84 tions for Mycobacterium tuberculosis against levofloxacin by the traditional reference method, agar p
85 (AORs) and 95% confidence intervals (CIs) of levofloxacin, ciprofloxacin, and moxifloxacin compared w
87 06 to November 2007, outpatient new users of levofloxacin, ciprofloxacin, moxifloxacin, cephalosporin
88 azithromycin, clarithromycin, moxifloxacin, levofloxacin, ciprofloxacin, or amoxicillin-clavulanate
90 was investigated at various temperatures and levofloxacin concentrations, and the activation energy w
91 andomized trial to determine whether a 5-day levofloxacin-containing quadruple concomitant regimen wa
95 ecommended rescue therapies include PBMT and levofloxacin-containing therapy (PPI + amoxicillin + lev
97 r quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which 90 percent of the
98 gorical agreements for the ciprofloxacin and levofloxacin Etests were 89.6 and 83.7%, respectively.
99 mized to receive either the oral concomitant levofloxacin, ethambutol, azithromycin, and rifampin (CL
100 A new regimen combining four antibiotics (levofloxacin, ethambutol, azithromycin, and rifamycin) h
101 th ticarcillin, gentamicin and vancomycin or levofloxacin eye drops leading to enucleation in one cas
102 Ceftolozane-tazobactam was non-inferior to levofloxacin for composite cure (306 [76.9%] of 398 vs 2
105 ant to the newer fluoroquinolones, including levofloxacin, gatifloxacin, gemifloxacin, and garenoxaci
108 mec-IV strains to clindamycin, erythromycin, levofloxacin, gentamicin, rifampin, minocycline, and tri
109 infection in 15.7 percent of patients in the levofloxacin group and 21.6 percent of patients in the p
110 he mean follow-up time was 46.5 weeks in the levofloxacin group and 46.3 weeks in the placebo group (
111 viruria occurred in 22 patients (29%) in the levofloxacin group and in 26 patients (33.3%) in the pla
112 rapy course, 10.8 percent of patients in the levofloxacin group had at least one febrile episode, as
113 chemotherapy, 3.5 percent of patients in the levofloxacin group had at least one febrile episode, as
114 lates usually sensitive to quinolones in the levofloxacin group vs placebo (14/24 [58.3%] vs 15/45 [3
116 s (minimum inhibitory concentration [MIC] to levofloxacin, > or = 0.125 microg/mL) were identified.
118 estis CO92 and given a subinhibitory dose of levofloxacin had acute inflammation, edema, and masses o
120 data support using targeted prophylaxis with levofloxacin in children undergoing induction chemothera
122 actam led to better responses than high-dose levofloxacin in patients with complicated lower-urinary-
124 y transplant recipients, a 3-month course of levofloxacin initiated early following transplantation d
126 stance to metronidazole, clarithromycin, and levofloxacin is more common among H. pylori isolates fro
130 cin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penicillin (PEN), te
131 eatments (Group B, n = 51) and no history of levofloxacin (LVX) consumption were prescribed pantopraz
134 loxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trimethoprim-su
136 l), ceftriaxone (MIC90s, 0.5 microg/ml), and levofloxacin (MIC90s, < or =0.03 to 0.06 microg/ml).
138 wide, and all patients colonized with FQREC (levofloxacin minimum inhibitory concentration, >/=8 mug/
140 findings were reported regarding the use of levofloxacin/moxifloxacin in the first-line treatment; t
145 ploratory data support offering prophylactic levofloxacin on cycle 1 only of myelosuppressive cancer
147 andomly assigned to receive either 500 mg of levofloxacin once daily or matching placebo for seven da
148 ultures showed that the strains resistant to levofloxacin or gatifloxacin were associated with higher
150 nteers, we confirmed the cross-reactivity of levofloxacin or ofloxacin with these opiate screening as
151 uveitis cases, current use of moxifloxacin, levofloxacin, or ciprofloxacin hydrochloride was compare
152 r rifampin, 97.6% for quinolones (ofloxacin, levofloxacin, or moxifloxacin), 99.2% for amikacin, 99.2
153 to clindamycin, tetracycline, erythromycin, levofloxacin, or mupirocin was detected in a large propo
159 ts, 173 received no prophylaxis, 69 received levofloxacin prophylaxis, and 102 received other prophyl
160 mes in patients who received no prophylaxis, levofloxacin prophylaxis, or other prophylaxis during in
162 tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable in
164 illin resistance in 10/531 (2%) persons, and levofloxacin resistance in 30/155 (19%) persons; no tetr
169 y tests with a subset of pan-susceptible and levofloxacin-resistant isolates validated the selected t
170 isolates and approximately one-third of the levofloxacin-resistant isolates were multidrug resistant
173 3,133 erythromycin-resistant strains and 81 levofloxacin-resistant strains, were collected from 206
176 evalence of resistance to clarithromycin and levofloxacin rose significantly over time during the per
180 ive antibiotics, amoxicillin, metronidazole, levofloxacin, tetracyclin, and clarithromycin, commonly
183 These findings do not support the use of levofloxacin to prevent posttransplant BK virus infectio
185 -generation fluoroquinolone (moxifloxacin or levofloxacin) use and patient mortality, adjusting for r
186 ast, susceptibility rates to clindamycin and levofloxacin varied from 94.0% and 60.7% (aged 6-17 year
189 A 10-day sequential regimen that contains levofloxacin was efficient, safe, and cost saving in era
192 atom in benzene ring attached to fluorine of levofloxacin was investigated by C K-edge X-ray absorpti
198 sted ORs for azithromycin, moxifloxacin, and levofloxacin were 2.62 (95% CI, 1.69-4.06), 2.31 (95% CI
200 ance rates to erythromycin, clindamycin, and levofloxacin were higher in the population aged >/= 65 y
201 whereas resistance rates to clindamycin and levofloxacin were lowest among isolates from patients ag
202 0), media containing subinhibitory levels of levofloxacin were prepared and stored at 4 and 37 degree
204 eneration of PPIs and use of moxifloxacin or levofloxacin within triple therapy as second-line treatm
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。